CJC-1295 without DAC research and evidence overview

This is the one compound in the CJC family with no trial of its own. The published CJC-1295 human study tested the DAC version — the one with the albumin-binding modification — and its results do not transfer to a short-acting peptide. What can honestly be said about the non-DAC version rests on two other bodies of work: the general GHRH(1-29) literature from the 1990s, which is real and human, and the DAC trial's mechanistic findings, which apply only partially. Anyone citing "the CJC-1295 study" for this product is citing a trial of a different molecule.

"CJC-1295 without DAC," "Modified GRF (1-29)," and "Mod GRF 1-29" all refer to a tetrasubstituted analogue of the first 29 amino acids of growth hormone-releasing hormone. The substitutions are there to resist enzymatic degradation; without the Drug Affinity Complex, the peptide's duration is measured in minutes to hours rather than days.

The name is the problem. CJC-1295 was developed as a long-acting compound specifically because of the DAC. Removing the DAC and keeping the name produces a molecule whose pharmacokinetics are the opposite of the one that was studied, while inheriting its citations. The functional description — a short-acting GHRH analogue closer in behaviour to sermorelin than to CJC-1295 with DAC — is more accurate than the marketing name.

Short-acting GHRH(1-29) has been given to humans in published research, and the findings are informative even though they used a different analogue.

In a study at the National Institute on Aging, 10 healthy non-obese old men (mean age 68) and 9 young men (mean age 26) underwent baseline 24-hour GH profiling; the older men then received both low-dose (0.5 mg) and high-dose (1 mg) subcutaneous GHRH(1-29) twice daily for 14 days, in randomised order with a 14-day washout (Corpas et al., JCEM 1992;75(2):530–535, PMID 1379256).

The high dose significantly increased mean 24-hour GH, area under GH peaks, peak amplitude, and IGF-I — enough that these measures no longer differed between the old and young groups. The low dose did not achieve significance. Fasting glucose, urinary C-peptide, blood pressure, and chemistry and haematology profiles were unaffected over the two weeks.

Two things follow. Frequent short-acting GHRH dosing can normalise an age-related decline in GH and IGF-I — a real pharmacodynamic result. And the authors' own conclusion stopped at "suggesting that prolonged treatment could improve age-related alterations in body composition" — a hypothesis, from a 14-day study measuring hormones, not body composition.

The published CJC-1295 trial found that a single injection raised GH 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with a half-life of 5.8 to 8.1 days (Teichman et al., JCEM 2006;91(3):799–805, PMID 16352683).

What transfers: the demonstration that this analogue backbone engages the GHRH receptor and drives GH release in humans. What does not transfer: every duration figure in that paper, since all of them are consequences of the DAC. Citing an 8-day half-life for a compound without the modification that produces it is a straightforward category error, and it appears frequently in vendor copy.

No published trial has reported dosing, pharmacokinetics, safety, or any outcome for the tetrasubstituted non-DAC analogue as sold. No study has compared it against sermorelin, against the DAC version, or against placebo in any population. There are no body-composition, strength, sleep, or recovery endpoints. There is no long-term safety data, and the chronic GH-axis questions — insulin sensitivity and glucose tolerance over years — remain open for the whole class.

The compound has no FDA-approved indication, and GHRH analogues are prohibited in sport by the World Anti-Doping Agency. The honest position is that the mechanism is credible and inherited from a well-understood hormone, while the specific molecule, at the doses used, has never been studied in people.